(2016) Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. Angew Chem Int Ed Engl 55: 7520-7524.Cao Y, Rodgers DT, Du J, Ahmad I, Hampton EN, Ma JS, Mazagova M, Choi SH, Yun HY, Xiao H, et al. Design of switchable chimeric antigen receptor T cells ...
observed lung toxicity was likely caused by the infusion of a large number of lymphocytes, which were trapped in the lungs, where low expression of the Her2 target antigen led to strong activation of the CAR T cells due to the additional costimulatory domains incorporated into the CAR design....
Sadelain M, Brentjens R, Riviere I . The basic principles of chimeric antigen receptor design.Cancer Discov2013;3: 388–398. ArticleCASPubMedPubMed CentralGoogle Scholar et alSci Transl Med
As mentioned above, identifying highly consistently expressed target tumor antigens is a critical step in CAR design. Most TAAs are also expressed by some healthy cells, potentially causing a “targeting nontumor” effect [148]. Furthermore, the expression of these TAAs can vary greatly among sin...
Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation SabrinaWright, ...FadiIssa, inEngineering, 2022 1Introduction Chimeric antigen receptors(CARs) are a breakthrough in the design and production of cells for adoptive cellular therapy (ACT...
Chimeric antigen receptor T (CAR-T) cells have demonstrated promising results against hematological malignancies, but have encountered significant challenges in translation to solid tumors. To overcome these hurdles, we have developed a switchable CAR-T cell platform in which the activity of the enginee...
Gross G, Waks T, Eshhar ZExpression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Nat A... To design and direct at will the specificity of T cells in a non-major histocompatibility complex (MHC)-restricted manner, we have gener...
Chimeric antigen receptor (CAR) T cell therapy, which targets tumors with high specificity through the recognition of particular antigens, has emerged as one of the most rapidly advancing modalities in immunotherapy, demonstrating substantial success aga
Chimeric Antigen Receptor (CAR) T-cell therapy, as an approved treatment option for patients with B cell malignancies, demonstrates that genetic modification of autologous immune cells is an effective anti-cancer regimen. Erythropoietin-producing Hepatoc
Notably, the mutations we generated to alter the PCPs maintain the antigen-binding affinity and specificity of the CAR. Therefore, our findings suggest that the rational tuning of PCPs to optimize tonic signaling and in vivo fitness of CAR-T cells is a promising design strategy for the next-...